SCHEMBL1574532

SCHEMBL1574532

O=C(Nc1cccc(Cl)c1)N1CC(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
LMNA P02545 2/20 0.50
NPSR1 Q6W5P4 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 1/20 0.47
RECQL P46063 1/20 0.47
KDM4E B2RXH2 1/20 0.47
LIPE Q05469 3/20 0.46
EPHX2 P34913 4/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
GAA P10253 1/20 0.45
GRIN2B Q13224 2/20 0.45
HCRTR1 O43613 1/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574964 0.91 BACE1 (0.49) MAPTLMNANPSR1KDM4ELIPE
SCHEMBL1574555 0.90 MAPT (0.54) MAPTLMNAMEN1KMT2ALIPE
SCHEMBL1574951 0.89 LMNA (0.65) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL1575480 0.88 MAPT (0.57) MAPTLMNAKDM4ELIPEEPHX2
SCHEMBL1574999 0.88 EPHX2 (0.53) MAPTLMNALIPEEPHX2CYP2C9
SCHEMBL1574765 0.88 LMNA (0.59) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL1575574 0.88 LIPE (0.47) MAPTLMNAKDM4ELIPEEPHX2
SCHEMBL1574647 0.88 LIPE (0.49) MAPTMEN1KMT2ALIPEEPHX2
SCHEMBL1574856 0.87 LMNA (0.48) MAPTLMNAMEN1KMT2AKDM4E
SCHEMBL1574496 0.86 LMNA (0.48) MAPTLMNAALDH1A1LIPEEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885LMNA 1076/4885NPSR1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.